OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: May 31, 2017 Report Code: GDHC066POA-ST

Select Item

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.
Key Questions Answered
How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015–2025?
What are the most promising late-stage pipeline drugs in ovarian cancer?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the unmet needs in ovarian cancer treatment management?
What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline ovarian cancer market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AB Science
AbbVie
Acerta
Aprea
Array BioPharma
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Celsion
Chugai Pharmaceutical
Clovis Oncology
Ganymed
Genentech
Gradalis
ImmunoGen
Immunovaccine
Incyte
Innate Pharma
Janssen
Mateon Therapeutics
MedImmune
Merck & Co.
Merck KGaA
Oasmia
Oncolytics Biotech
Ono Phamaceutical
Pfizer
PharmaMar
Prima BioMed
PsiOxus Therapeutics
Roche
Sotio
Taiho Pharmaceutical
Tesaro
VentiRx

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025

2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers

2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM’s Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer’s First-to-Market Bavencio

2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Staging Systems

4.3 Risk Factors, Symptoms, and Screening

4.4 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global Trends

5.3.1 7MM Incidence Trends

5.3.2 7MM Trends in Relative Survival

5.4 Forecast Methodology

5.4.1 Sources Used Tables

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for Ovarian Cancer (2015–2025)

5.5.1 Diagnosed Incident Cases of Ovarian Cancer

5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer

5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer

5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines

6.3 Clinical Practice and Leading Prescribed Drugs

6.4 Product Profiles – Major Brands, Angiogenesis Inhibitors

6.4.1 Avastin (bevacizumab)

6.5 Product Profiles – Major Brands, PARP Inhibitors

6.5.1 Lynparza (olaparib)

6.5.2 Rubraca (rucaparib)

6.5.3 Zejula (niraparib)

6.6 Product Profiles – Major Brands, Next-Generation Chemotherapies

6.6.1 Yondelis (trabectedin)

6.7 Generic Chemotherapy

6.7.1 Front-Line Treatment (Adjuvant/First Line)

6.7.2 Recurrent Disease

7 Unmet Needs Assessment and Opportunity Analysis

7.1 Overview

7.2 Improved First-line Therapies

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Individualized Treatment Approaches

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 An Early Stage Diagnostic for Ovarian Cancer

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 Research and Development Strategies

8.1 Overview

8.1.1 Optimizing Chemotherapy

8.1.2 Targeted Therapies – A Patient Specific Approach

8.1.3 Immunotherapies – A Patient Specific Approach

8.1.4 Combination Therapies

8.1.5 Licenses and Alliances

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Endpoints

8.2.2 The Future of Clinical Trial Endpoints

8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Product Profiles – Immune Checkpoint Modulators

9.2.1 Bavencio (avelumab)

9.2.2 Opdivo (nivolumab)

9.2.3 Tecentriq (atezolizumab)

9.3 Product Profiles – Cancer Vaccines

9.3.1 Vigil (gemogenovatucel-T)

9.4 Product Profiles – Vascular Disrupting Agents

9.4.1 Fosbretabulin tromethamine

9.5 Product Profiles – PARP Inhibitors

9.5.1 Veliparib

9.6 Product Profiles – Targeted Cytotoxic Therapies (Antibody-Drug Conjugates)

9.6.1 Mirvetuximab soravtansine

9.7 Product Profiles – Next-Generation Chemotherapies

9.7.1 Opaxio (paclitaxel poliglumex)

9.7.2 Lurbinectedin

9.7.3 Apealea/Paclical (paclitaxel)

9.8 Innovative Early Stage Approaches

9.8.1 Immune Checkpoint Modulators

9.8.2 Oncolytic Viruses

9.8.3 Angiogenesis Inhibitors

9.8.4 Interleukin-12 Agonists

9.8.5 Toll-Like Receptor 8 Agonists

9.8.6 Cancer Vaccines

9.8.7 Kinase Inhibitors

9.8.8 Targeted Cytotoxic Therapies

9.8.9 P53 Agonists

9.9 Other Notable Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Products

10.2 Commercial Benchmark of Key Pipeline Therapies

10.3 Competitive Assessment

10.4 Top-Line Ten-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Percentage of Drug-Treated Patients

11.4.2 Drugs Included in Each Therapeutic Class

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Average Body Weight and Surface Area Across the 7MM

11.4.6 General Forecast Assumptions

11.4.7 Individual Drug Assumptions

11.4.8 Generic and Biosimilar Erosion

11.4.9 Pricing of Pipeline Agents

11.5 Primary Research

11.5.1 Physicians and Specialists Included in This Study

11.5.2 Online Survey of High-Prescribing Physicians

11.6 About the Authors

11.6.1 Analysts

11.6.2 Epidemiologist

11.6.3 Therapy Area Director

11.6.4 Global Director of Therapy Analysis and Epidemiology

11.6.5 Global Head of Healthcare

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table

Table 1: Ovarian Cancer: Key Metrics in the 7MM

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum

Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016

Table 4: Risk Factors of OC

Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC

Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC

Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025

Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015

Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025

Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025

Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM

Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease

Table 13: Product Profile – Avastin

Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer

Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer

Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer

Table 17: Grade ≥3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer

Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017

Table 19: Product Profile – Lynparza

Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial

Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer

Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer

Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19

Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017

Table 25: Product Profile – Rubraca

Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer

Table 27: Most Common AEs Reported in ≥20% of Patients in Study 10 and ARIEL2

Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017

Table 29: Product Profile – Zejula

Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer

Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula

Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017

Table 33: Product Profile – Yondelis

Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer

Table 35: Most Commonly Reported Grade 3 and 4 AEs in ≥5% of Patients in OVA-301

Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017

Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer

Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer

Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer

Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment

Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer

Table 42: Unmet Needs and Opportunities in Ovarian Cancer

Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer.

Table 44: Potential New Classification System for Recurrent Ovarian Cancer

Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017

Table 46: Product Profile – Bavencio

Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016

Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015

Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015

Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016

Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017

Table 52: Product Profile – Opdivo

Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714)

Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo

Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017

Table 56: Product Profile – Tecentriq

Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017

Table 58: Product Profile – Vigil (gemogenovatucel-T)

Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial

Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials

Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017

Table 62: Product Profile – Fosbretabulin Tromethamine

Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer

Table 64: Grade ≥2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer

Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017

Table 66: Product Profile – Veliparib

Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer

Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial

Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017

Table 70: Product Profile – Mirvetuximab soravtansine

Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017

Table 74: Product Profile – Opaxio

Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer

Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer

Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017

Table 78: Product Profile – Lurbinectedin

Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer

Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer

Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017

Table 82: Product Profile – Apealea

Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer

Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer

Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017

Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017

Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy

Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda

Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab

Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat

Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab

Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin

Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev

Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer

Table 95: Summary of Grade ≥3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer

Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017

Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1

Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod

Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac

Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa

Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac

Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib

Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef

Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib

Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib

Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027

Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246

Table 108: Other Notable Ovarian Cancer Products in Development, 2017

Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products

Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued

Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products

Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued

Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015–2025 ($M)

Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015–2025

Table 115: Ovarian Cancer Products Market – Drivers and Barriers, 2015–2025

Table 116: Ovarian Cancer Patient Population segmentations in the 7MM – Secondary Sources Leveraged

Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class

Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM

Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM

Table 120: Average Body Weight and Surface Area Across the 7MM

Table 121: Average Cost of Therapy of Avastin in the 7MM

Table 122: Average Cost of Therapy of Lynparza in the 7MM

Table 123: Average Cost of Therapy of Rubraca in the US and 5EU

Table 124: Average Cost of Therapy of Yondelis in the 7MM

Table 125: Average Cost of Therapy of Votrient in the 7MM

Table 126: Average Cost of Therapy of Zejula in the US and 5EU

Table 127: Average Cost of Therapy of Veliparib in the 7MM

Table 128: Average Cost of Therapy of Bavencio in the 7MM

Table 129: Average Cost of Therapy of Tecentriq in the 7MM

Table 130: Average Cost of Therapy of Opdivo in the 7MM

Table 131: Average Cost of Therapy of Vigil in the 7MM

Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM

Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU

Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM

Table 135: Average Cost of Therapy of Apealea in the US and 5EU

Table 136: High-Prescribing Physicians Surveyed, by Country

Figures

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025

Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017

Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms

Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer

Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998─2007

Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015

Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages≥18 Years, Cases per 100,000, 2015

Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025

Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025

Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients

Figure 12: Clinical Development Program for Avastin in Ovarian Cancer

Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer

Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer

Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer

Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer

Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer

Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer

Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer

Figure 20: Clinical Development Program for Vigil in Ovarian Cancer

Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer

Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer

Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer

Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer

Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer

Figure 26: Clinical Development Program for Apealea in Ovarian Cancer

Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer

Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017

Figure 29: Sales for Ovarian Cancer Products by Region, 2015–2025

Frequently asked questions

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 in real time.

  • Access a live OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more